Gibson Dunn Advises XOMA Royalty Corporation in Connection with Acquisition of ESSA Pharma by XenoTherapeutics
Firm News | July 21, 2025
Gibson Dunn represented XOMA Royalty Corporation in connection with the acquisition of ESSA Pharma Inc. (Nasdaq: EPIX) by XenoTherapeutics, Inc., where XOMA Royalty is acting as structuring agent and guarantor and will provide financing to XenoTherapeutics in connection with the transaction. ESSA is a pharmaceutical company that was previously focused on developing novel and proprietary therapies for the treatment of patients with prostate cancer. The transaction, which signed on July 14, 2025, is expected to close in the third quarter of 2025.
Gibson Dunn regularly advises life sciences companies and investors on complex mergers, acquisitions, and related financing transactions in the pharmaceutical sector.
The Gibson Dunn team included Ryan Murr, Branden Berns, Evan Shepherd, Advait Ramanan, Hunter Michielson, and Risa Nakagawa. Team members advising on additional aspects of the transaction include Pamela Lawrence Endreny and Bree Gong (tax) and Sean Feller (executive benefits).